Literature DB >> 22775446

Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation.

Xue Song1, Stephen D Sander, Helen Varker, Alpesh Amin.   

Abstract

BACKGROUND AND
OBJECTIVE: No study has been published that compared persistence and discontinuation of warfarin with other long-term medications in patients with atrial fibrillation (AF). The objective of this study was to evaluate persistence and discontinuation patterns in AF patients taking warfarin and other common long-term medications and identify predictors of persistence and discontinuation in this population.
METHODS: Patients with warfarin prescription within 3 months after AF hospitalization discharge and 12-month data before and after the first prescription were evaluated using administrative claims data (1 January 2005 - 31 December 2007). For comparison, persistence patterns for other long-term medications for treatment of hypertension, hyperglycemia, heart disease, and dyslipidemia, including once- (od) and twice- (bid) daily medications, were evaluated. Non-persistence was defined as the presence of a ≥60-day gap in medication use. Permanent discontinuation was defined as no use of the medication for ≥90 days until the end of the follow-up period. Multivariate analysis was conducted to identify predictors of warfarin non-persistence and discontinuation.
RESULTS: 28 384 patients with AF were identified; 16 036 (56.5%) had a warfarin prescription following AF hospitalization. 53.5% of warfarin users were persistent for at least 1 year, similar to other long-term medications commonly prescribed to the AF population (ranging between 45.2% and 61.3%). 42.6% of warfarin users permanently discontinued warfarin within 1 year, also consistent with the discontinuation rate of 32.9-52.0% of other long-term medications. Residence in the South and West regions of the US, history of cardiac dysrhythmias, and warfarin cost-sharing significantly decreased the likelihood of warfarin persistence and increased the likelihood of discontinuation, while older age, history of ischemic stroke, and warfarin use before hospitalization significantly increased warfarin persistence and decreased the likelihood of discontinuation. Adherence of od and bid medications was similar.
CONCLUSION: Persistence and discontinuation with warfarin in patients with AF is consistent with other long-term medications. Identifying factors associated with non-persistence and discontinuation with long-term medications can help in developing targeted adherence programs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22775446     DOI: 10.1007/BF03261833

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  10 in total

Review 1.  Drug adherence in patients taking oral anticoagulation therapy.

Authors:  Sebastian Ewen; Volker Rettig-Ewen; Felix Mahfoud; Michael Böhm; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2013-09-03       Impact factor: 5.460

2.  Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients.

Authors:  Thomas Wilke; Antje Groth; Andreas Fuchs; Matthias Pfannkuche; Ulf Maywald
Journal:  Eur J Clin Pharmacol       Date:  2017-08-05       Impact factor: 2.953

3.  Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States.

Authors:  Steven B Deitelzweig; Michael Evans; Jeffrey Trocio; Kiran Gupta; Melissa Lingohr-Smith; Brandy Menges; Jay Lin
Journal:  Clin Appl Thromb Hemost       Date:  2017-01-31       Impact factor: 2.389

4.  Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy.

Authors:  Daniel L Labovitz; Laura Shafner; Morayma Reyes Gil; Deepti Virmani; Adam Hanina
Journal:  Stroke       Date:  2017-04-06       Impact factor: 7.914

5.  Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.

Authors:  Tomas Forslund; Björn Wettermark; Paul Hjemdahl
Journal:  Eur J Clin Pharmacol       Date:  2015-11-27       Impact factor: 2.953

6.  Predicting prolonged dose titration in patients starting warfarin.

Authors:  Brian S Finkelman; Benjamin French; Luanne Bershaw; Colleen M Brensinger; Michael B Streiff; Andrew E Epstein; Stephen E Kimmel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-07-26       Impact factor: 2.890

Review 7.  Atrial fibrillation management in older heart failure patients: a complex clinical problem.

Authors:  Giovanni Pulignano; Donatella Del Sindaco; Maria Denitza Tinti; Stefano Tolone; Giovanni Minardi; Antonio Lax; Massimo Uguccioni
Journal:  Heart Int       Date:  2016-09-22

8.  Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria.

Authors:  Andreas Clemens; Herbert Noack; Martina Brueckmann; Gregory Y H Lip
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

9.  Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.

Authors:  Ryan T Borne; Colin O'Donnell; Mintu P Turakhia; Paul D Varosy; Cynthia A Jackevicius; Lucas N Marzec; Frederick A Masoudi; Paul L Hess; Thomas M Maddox; P Michael Ho
Journal:  BMC Cardiovasc Disord       Date:  2017-09-02       Impact factor: 2.298

10.  Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry.

Authors:  Sergio Dubner; José Francisco Kerr Saraiva; Juan Carlos Nunez Fragoso; Gonzalo Barón-Esquivias; Christine Teutsch; Venkatesh Kumar Gurusamy; Sabrina Marler; Menno V Huisman; Gregory Y H Lip; Cecilia Zeballos
Journal:  Int J Cardiol Heart Vasc       Date:  2020-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.